Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash. This acquisition is highly complementary to Thermo Fisher’s existing bioproduction business, aiming to strengthen its offerings in the rapidly growing bioprocessing market.
Solventum’s Purification & Filtration business, which generated approximately $1 billion in revenue in 2024, provides purification and filtration technologies crucial for the production of biologics, medical technologies, and industrial applications. The integration of this innovative filtration portfolio will broaden Thermo Fisher’s capabilities across upstream and downstream workflows in biologics development and manufacturing.
The transaction is expected to close by the end of 2025, subject to customary closing conditions and regulatory approvals. While it is anticipated to be dilutive to adjusted EPS by $0.06 in the first year of ownership (excluding financing costs), it is expected to be accretive by $0.28 in that period and realize approximately $125 million of adjusted operating income from revenue and cost synergies by year five.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.